atropine sulfate injection, USP Highlights

()

HIGHLIGHTS OF PRESCRIBING INFORMATION

These highlights do not include all the information needed to use ATROPINE SULFATE INJECTION safely and effectively. See full prescribing information for ATROPINE SULFATE INJECTION.
ATROPINE SULFATE INJECTION, for intravenous use
Initial U.S. Approval: 1960

INDICATIONS AND USAGE

Atropine is a muscarinic antagonist indicated for temporary blockade of severe or life threatening muscarinic effects. (1)

DOSAGE AND ADMINISTRATION

For intravenous administration (2.1)
Titrate according to heart rate, PR interval, blood pressure and symptoms (2.1)
Adult dosage
-
Antisialagogue or for antivagal effects: Initial single dose of 0.5 mg to 1 mg (2.2)
-
Antidote for organophosphorus or muscarinic mushroom poisoning: Initial single dose of 2 mg to 3 mg, repeated every 20-30 minutes (2.2)
-
Bradyasystolic cardiac arrest: 1 mg dose, repeated every 3-5 minutes if asystole persists (2.2)
Patients with Coronary Artery Disease: Limit the total dose to 0.03 mg/kg to 0.04 mg/kg (2.4)

DOSAGE FORMS AND STRENGTHS

0.05 mg/mL injection in Ansyr™ Plastic Syringe (3)
0.1 mg/mL injection in Ansyr™ Plastic Syringe (3)
0.1 mg/mL injection in LifeShield™ Abboject™ Glass Syringe (3)

CONTRAINDICATIONS

None. (4)

WARNINGS AND PRECAUTIONS

  • Tachycardia (5.1)
  • Glaucoma (5.2)
  • Pyloric obstruction (5.3)
  • Worsening urinary retention (5.4)
  • Viscid bronchial plugs (5.5)

ADVERSE REACTIONS

Most adverse reactions are directly related to atropine's antimuscarinic action. Dryness of the mouth, blurred vision, photophobia and tachycardia commonly occur with chronic administration of therapeutic doses. (6)

To report SUSPECTED ADVERSE REACTIONS, contact Hospira, Inc. at 1-800-441-4100, or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

DRUG INTERACTIONS

Mexiletine: Decreases rate of mexiletine absorption. (7.1)

Revised: 6/2020

Find atropine sulfate injection, USP medical information:

Find atropine sulfate injection, USP medical information:

Our scientific content is evidence-based, scientifically balanced and non-promotional. It undergoes rigorous internal medical review and is updated regularly to reflect new information.

atropine sulfate injection, USP Quick Finder

Prescribing Information
Download Prescribing Information

Health Professional Information

Highlights

HIGHLIGHTS OF PRESCRIBING INFORMATION

These highlights do not include all the information needed to use ATROPINE SULFATE INJECTION safely and effectively. See full prescribing information for ATROPINE SULFATE INJECTION.
ATROPINE SULFATE INJECTION, for intravenous use
Initial U.S. Approval: 1960

INDICATIONS AND USAGE

Atropine is a muscarinic antagonist indicated for temporary blockade of severe or life threatening muscarinic effects. (1)

DOSAGE AND ADMINISTRATION

For intravenous administration (2.1)
Titrate according to heart rate, PR interval, blood pressure and symptoms (2.1)
Adult dosage
-
Antisialagogue or for antivagal effects: Initial single dose of 0.5 mg to 1 mg (2.2)
-
Antidote for organophosphorus or muscarinic mushroom poisoning: Initial single dose of 2 mg to 3 mg, repeated every 20-30 minutes (2.2)
-
Bradyasystolic cardiac arrest: 1 mg dose, repeated every 3-5 minutes if asystole persists (2.2)
Patients with Coronary Artery Disease: Limit the total dose to 0.03 mg/kg to 0.04 mg/kg (2.4)

DOSAGE FORMS AND STRENGTHS

0.05 mg/mL injection in Ansyr™ Plastic Syringe (3)
0.1 mg/mL injection in Ansyr™ Plastic Syringe (3)
0.1 mg/mL injection in LifeShield™ Abboject™ Glass Syringe (3)

CONTRAINDICATIONS

None. (4)

WARNINGS AND PRECAUTIONS

  • Tachycardia (5.1)
  • Glaucoma (5.2)
  • Pyloric obstruction (5.3)
  • Worsening urinary retention (5.4)
  • Viscid bronchial plugs (5.5)

ADVERSE REACTIONS

Most adverse reactions are directly related to atropine's antimuscarinic action. Dryness of the mouth, blurred vision, photophobia and tachycardia commonly occur with chronic administration of therapeutic doses. (6)

To report SUSPECTED ADVERSE REACTIONS, contact Hospira, Inc. at 1-800-441-4100, or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

DRUG INTERACTIONS

Mexiletine: Decreases rate of mexiletine absorption. (7.1)

Revised: 6/2020

Resources

Didn’t find what you were looking for? Contact us.

MI Digital Assistant

Chat online with Pfizer Medical Information regarding your inquiry on a Pfizer medicine.

Call 800-438-1985*

*Contact Medical Information. 8AM-9PM ET Monday to Friday; excluding holidays.

Medical Inquiry

Submit a medical question for Pfizer prescription products.

Report Adverse Event

Pfizer Safety

To report an adverse event related to the Pfizer-BioNTech COVID-19 Vaccine, and you are not part of a clinical trial* for this product, click the link below to submit your information:

Pfizer Safety Reporting Site

*If you are involved in a clinical trial for this product, adverse events should be reported to your coordinating study site.

If you cannot use the above website, or would like to report an adverse event related to a different Pfizer product, please call Pfizer Safety at (800) 438-1985.

FDA Medwatch

You may also contact the U.S. Food and Drug Administration (FDA) directly to report adverse events or product quality concerns either online at www.fda.gov/medwatch or call (800) 822-7967.